Figure 4
From: Characterization of pancreatic cancer with ultra-low tumor mutational burden
A prognostic analysis according to the TMB classification. (a) In the TMB-ultra-low group, the OS was significantly better than in the TMB-low group (median, 39.2 vs. 19.2 months; P = 0.023). (b) TMB-low PC tended to have a poorer recurrence-free survival (RFS) than TMB-ultralow, although the difference in the RFS did not reach significance (median, 8.1 vs. 13.9 months; P = 0.068).
